Drug Trial Radar · NCT06678074
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Feb 6, 2025
Primary completion
Aug 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Implicit BioscienceIndustry
- Sponsor type
- Industry
- Collaborators
- Washington University School of Medicine; University of Virginia
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).
Conditions
- STEMI
- STEMI (ST Elevation MI)
- STEMI - ST Elevation Myocardial Infarction (MI)
- Stent Implantation
Interventions
Atibuclimab (IC14), 20 mg/kg intravenously, onceDrug
monoclonal antibody against CD14
Placebo, 150 mL intravenously, onceOther
sterile normal saline for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (safety and tolerability)Time frame: Day 1-29
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.